Aerovate Therapeutics, Inc.
AVTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4 | $3 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $2 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -5,709.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -4,848.2% |
| EPS Diluted | -482.25 | -863.46 | -0.09 | -0.19 |
| % Growth | 44.1% | -959,300% | 52.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |